M&T Bank Corp Adagio Therapeutics, Inc. Transaction History
M&T Bank Corp
- $28.9 Billion
- Q3 2025
Shares
2 transactions
Others Institutions Holding ADGI
# of Institutions
83Shares Held
153MCall Options Held
244KPut Options Held
167K-
Janus Henderson Group PLC London, X025.4MShares$84 Million0.04% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct20.3MShares$67.2 Million0.13% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx19MShares$62.8 Million0.93% of portfolio
-
Ra Capital Management, L.P. Boston, MA17.1MShares$56.7 Million0.97% of portfolio
-
Mithril Ii Gp LP Austin, TX11.2MShares$37.2 Million19.18% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...